Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: The aim of the present study was to observe the effect of sacubitril valsartan on cardiac function and vascular endothelial function in patients with chronic heart failure with reduced ejection fraction (HFrEF).
Methods: A total of 80 patients with HFrEF were randomly divided into an observation group and a control group, with 40 patients in each group. Sacubitril valsartan was added to the conventional treatment in the observation group, and perindopril was added to the conventional treatment in the control group. Both groups were treated continuously for 12 weeks. The left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), flow-mediated vasodilatory function (FMD) of the brachial artery, and levels of plasma Ang II, endothelin 1 (ET-1), and calcitonin gene-related peptide (CGRP), together with the serum nitric oxide (NO) and NO synthase (NOS) were compared before and after treatment in the groups.
Results: Before the treatment, the levels of LVEF, LVEDD, FMD, Ang II, ET-1, CGRP, NO, and NOS in the observation group were not significantly different from those in the control group (P > 0.05). However, the levels of LVEF, FMD, CGRP, NO, and NOS in both groups were significantly higher after the treatment than those before the treatment (P < 0.05) and significantly higher in the observation group than those in the control group. The difference was statistically significant (P < 0.05). Meanwhile, the levels of LVEDD, Ang II, and ET-1 in both groups decreased significantly after the treatment (P < 0.05) and were significantly lower in the observation group than those in the control group. The difference was statistically significant (P < 0.05).
Conclusion: Sacubitril valsartan might improve endothelial function while increasing cardiac function in HFrEF patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3233/CH-201032 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of sacubitril/valsartan in end-stage renal disease patients with heart failure: a review.
Ann Med
December 2025
Department of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu, China.
Purpose: End-stage renal disease (ESRD) is associated with a heavy global public health burden and an increased risk of cardiovascular diseases. Sacubitril/valsartan has been shown to improve cardiovascular outcomes in patients with heart failure and delay the progression of chronic kidney disease. We aim to perform a comprehensive analysis of current clinical evidence on the use of sacubitril/valsartan in ESRD patients.
View Article and Find Full Text PDFComparison of renal effects between sacubitril/valsartan and thiazide diuretics among patients with uncontrolled hypertension and chronic kidney disease in Japan.
Clin Exp Nephrol
September 2025
Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Background: Sacubitril/valsartan is typically prescribed for patients with heart failure and hypertension. We previously reported that sacubitril/valsartan provides comparable blood pressure (BP) reduction and superior tolerability compared to thiazide diuretics. This post hoc study aimed to compare the effects of sacubitril/valsartan and thiazide diuretics in patients with chronic kidney disease (CKD).
View Article and Find Full Text PDFSacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial.
Eur J Heart Fail
September 2025
Brazilian Clinical Research Institute (BCRI), São Paulo, Brazil.
Aims: The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC). We describe the baseline characteristics of participants in PARACHUTE-HF compared with prior HFrEF trials.
Methods And Results: PARACHUTE-HF, a multicentre, active-controlled, open-label trial, enrolled 922 participants with confirmed CCC, New York Heart Association (NYHA) functional class II-IV, and left ventricular ejection fraction (LVEF) ≤40%.
Efficacy and safety of sacubitril-valsartan in Maintenance Hemodialysis patients with hypertension:A retrospective study.
PLoS One
September 2025
Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University, China.
Background: Hypertension is associated with elevated mortality rates among individuals on maintenance hemodialysis (MHD). However, there is limited information regarding the efficacy and safety of sacubitril-valsartan (SV) in MHD patients suffering from hypertension. Consequently, this study aims to evaluate the efficacy and safety of SV in this specific patient population.
View Article and Find Full Text PDFRepurposing Artrestan (Sacubitril/Valsartan), unveiling its anti-inflammatory and fibrinolytic properties in ulcerative colitis in rats.
Iran J Basic Med Sci
January 2025
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Objectives: Ulcerative colitis (UC) is an inflammatory disorder that is managed with various treatments, which have varying degrees of effectiveness and side effects, highlighting the need for new and more effective alternatives. In this study, we applied Artrestan (Sacubitrol/Valsartan), which has potent anti-inflammatory properties, alone or in combination with mesalazine, in the treatment of UC animal models.
Materials And Methods: Thirty male rats were randomly divided into control, colitis, Artrestan (60 mg/kg/day), mesalazine (100 mg/kg/day), and Artrestan plus mesalazine groups.